112 related articles for article (PubMed ID: 10479405)
1. In vitro modulation of cisplatin resistance by cytokines.
Poppenborg H; Knüpfer MM; Galla HJ; Wolff JE
Cytokine; 1999 Sep; 11(9):689-95. PubMed ID: 10479405
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
[TBL] [Abstract][Full Text] [Related]
3. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Borsellino N; Belldegrun A; Bonavida B
Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
[TBL] [Abstract][Full Text] [Related]
4. Effect induced by interleukin-1 on the behaviour of B16F10 melanoma cells.
De Galdeano AG; Boyano D; Cañavate L
Oncol Rep; 1999; 6(1):225-8. PubMed ID: 9864433
[TBL] [Abstract][Full Text] [Related]
5. The antiproliferative effect of trans-retinoic acid is associated with selective induction of interleukin-1 beta, a cytokine that directly inhibits growth of lung cancer cells.
Ross HJ
Oncol Res; 1996; 8(4):171-8. PubMed ID: 8869967
[TBL] [Abstract][Full Text] [Related]
6. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line.
Dedoussis GV; Mouzaki A; Theodoropoulou M; Menounos P; Kyrtsonis MC; Karameris A; Maniatis A
Exp Cell Res; 1999 Jun; 249(2):269-78. PubMed ID: 10366426
[TBL] [Abstract][Full Text] [Related]
7. Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells.
Tallen G; Riabowol K; Wolff JE
Anticancer Res; 2003; 23(2B):1631-5. PubMed ID: 12820433
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1beta-induced expression of IL-6 and production of human chorionic gonadotropin in human trophoblast cells via nuclear factor-kappaB activation.
Tsukihara S; Harada T; Deura I; Mitsunari M; Yoshida S; Iwabe T; Terakawa N
Am J Reprod Immunol; 2004 Sep; 52(3):218-23. PubMed ID: 15373762
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin induces radioprotection in human T98G glioma cells.
Poppenborg H; Münstermann G; Knüpfer MM; Hotfilder M; Hacker-Klom U; Wolff JE
Anticancer Res; 1997; 17(2A):1131-4. PubMed ID: 9137460
[TBL] [Abstract][Full Text] [Related]
11. Possible role of interleukin-1 in the regulation of bovine corpus luteum throughout the luteal phase.
Nishimura R; Bowolaksono A; Acosta TJ; Murakami S; Piotrowska K; Skarzynski DJ; Okuda K
Biol Reprod; 2004 Nov; 71(5):1688-93. PubMed ID: 15253926
[TBL] [Abstract][Full Text] [Related]
12. Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis.
Shlopov BV; Gumanovskaya ML; Hasty KA
Arthritis Rheum; 2000 Jan; 43(1):195-205. PubMed ID: 10643716
[TBL] [Abstract][Full Text] [Related]
13. Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro.
Mariani L; Beaudry C; McDonough WS; Hoelzinger DB; Kaczmarek E; Ponce F; Coons SW; Giese A; Seiler RW; Berens ME
Clin Cancer Res; 2001 Aug; 7(8):2480-9. PubMed ID: 11489830
[TBL] [Abstract][Full Text] [Related]
14. [Interleukin-6 functions as an autocrine growth stimulator for a human lung adenocarcinoma cell line PAa].
Fu J; Fang W; Zheng J
Zhonghua Zhong Liu Za Zhi; 1997 Jan; 19(1):45-8. PubMed ID: 10743055
[TBL] [Abstract][Full Text] [Related]
15. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
[TBL] [Abstract][Full Text] [Related]
16. IL-6 upregulates protein S expression in the HepG-2 hepatoma cells.
Hooper WC; Phillips DJ; Ribeiro M; Benson J; Evatt BL
Thromb Haemost; 1995 May; 73(5):819-24. PubMed ID: 7482409
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment.
Ikeguchi M; Nakamura S; Kaibara N
Oncol Rep; 2002; 9(5):1121-6. PubMed ID: 12168083
[TBL] [Abstract][Full Text] [Related]
18. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6.
Okamoto M; Kawamata H; Kawai K; Oyasu R
Cancer Res; 1995 Oct; 55(20):4581-5. PubMed ID: 7553633
[TBL] [Abstract][Full Text] [Related]
20. C6 cells cross-resistant to cisplatin and radiation.
Poppenborg H; Münstermann G; Knüpfer MM; Hotfilder M; Wolff JE
Anticancer Res; 1997; 17(3C):2073-7. PubMed ID: 9216666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
